Ignite Creation Date:
2024-05-06 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:18 PM
Study NCT ID:
NCT06205797
Status:
RECRUITING
Last Update Posted:
2024-01-17
First Post:
2024-01-04
Brief Title:
To Evaluate HU-045 in the Treatment of Glabellar LinesPhase III
Sponsor:
Huons Biopharma
Organization:
Huons Biopharma
Study Overview
Official Title:
A Multicenter Double-blind Randomized Parallel Active-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of HU-045 Compared to Xeomin in Adult Patients With Moderate or Severe Glabellar Lines
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Multicenter Double-blind Randomized Parallel Active-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin in Patients With Moderate to Severe Glabellar Lines
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None